Apogee to Present phase 1 Clinical Trial Results at the 2013 Molecular Targets and Cancer Therapeutics Meeting
Published: Oct 01, 2013
Apogee will present interim data from the first-in-human trial of ABC294640 entitled “A Phase I, Open-Label, Dose-Escalation Safety, Pharmacokinetic and Pharmacodynamic Study of ABC294640 in Patients with Advanced Solid Tumors” at the Molecular Targets and Cancer Therapeutics meeting in Boston on Tuesday, October 22.
Help employers find you! Check out all the jobs and post your resume.